CancerA1DE

CancerA1DE applies supervised machine learning to multianalyte blood test data to improve early cancer detection sensitivity and specificity.

Key Features:

• Enhanced Sensitivity: Achieves up to 77% sensitivity for Stage I cancers at 99% specificity, doubling prior sensitivity from 38%.
• Broad Applicability: Reaches approximately 90% sensitivity for Stage II cancers across multiple cancer types and increases breast cancer detection sensitivity from 30% to ~70% at 99% specificity.
• Data-Driven Insights: Employs model and data analysis to elucidate biomarkers and mechanisms that contribute to improved early-stage detection performance.

Scientific Applications:

• Early-stage cancer detection: Improves identification of Stage I and II cancers from blood-based multianalyte assays.
• Breast cancer screening: Enhances blood-based breast cancer detection sensitivity while maintaining high specificity (99%).
• Oncological research and diagnostics: Supports biomarker discovery and model-driven analysis for translational research and clinical diagnostic development.

Methodology:

Explores various supervised learning approaches tailored to multianalyte blood test data to detect subtle patterns and biomarkers indicative of early-stage cancers.